Supernus Pharmaceuticals, Inc. (SUPN)

NGM – Real Time Price. Currency in USD

46.76

-0.12 (-0.26%)

Market open: Aug 12, 2026, 2:49 PM EDT

46.88

0.00 (0.00%)

Previous after-hours: Aug 11, 2026, 7:34 PM EDT

07.08.2026

SUPN vs. TEVA: Which Stock Should Value Investors Buy Now?

Investors with an interest in Medical - Generic Drugs stocks have likely encountered both Supernus Pharmaceuticals (SUPN) and Teva Pharmaceutical Industries Ltd. (TEVA). But which of these two stocks is more attractive to value investors?

07.08.2026

Supernus Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Supernus Pharmaceuticals, Inc. - SUPN

NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Supernus Pharmaceuticals, Inc. (NasdaqGM: SUPN) to Indivior Pharmaceuticals, Inc. (Nasdaq: INDV). Under the terms of the proposed transaction, shareholders of Supernus will receive 1.5401 common shares of Indivior for each share of Supernus that they own. KSF is seeking to determine whether this con.

07.08.2026

New Strong Buy Stocks for August 7th

EDRY, OPBK, SUPN, MSBI and NXRT have been added to the Zacks Rank #1 (Strong Buy) List on August 7th, 2026.

07.08.2026

Best Value Stocks to Buy for August 7th

BCAL, SUPN and NXRT made it to the Zacks Rank #1 (Strong Buy) value stocks list on August 7th, 2026.

04.08.2026

INDV to Merge With Supernus, Beats on Q2 Earnings, Raises '26 Outlook

Indivior announces a merger with Supernus to form a CNS-focused biopharma company, tops Q2 earnings and revenue estimates and raises its 2026 outlook.

03.08.2026

Why Supernus Pharmaceuticals Stock Topped the Market Today

The two companies will carry the Supernus name. Supernus also published its latest quarterly earnings release.

03.08.2026

Supernus Pharmaceuticals, Inc. (SUPN) M&A Call Transcript

Videos

No Data

There is no data to display

Press releases

07.08.2026

Supernus Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Supernus Pharmaceuticals, Inc. - SUPN

03.08.2026

$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN)

NEW YORK, Aug. 3, 2026 /PRNewswire/ -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2025 ISS Securities Class Action Services Report. The firm is headquartered at the Empire State Building in New York City and is investigating Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN ) related to its sale to Indivior Pharmaceuticals, Inc. Under the terms of the proposed transaction, Supernus shareholders are expected to receive 1.5401 common shares of Indivior for each share of Supernus.

03.08.2026

Shareholder Alert: Ademi LLP investigates whether Supernus Pharmaceuticals, Inc. is obtaining a Fair Price for Public Shareholders

MILWAUKEE, Aug. 3, 2026 /PRNewswire/ -- Ademi LLP is investigating Supernus (Nasdaq: SUPN) for possible breaches of fiduciary duty and other violations of law in its recently announced transaction with Indivior Pharmaceuticals. Click here to learn how to join our investigation and obtain additional information or contact us at [email protected] or toll-free: 866-264-3995.

03.08.2026

SUPN Stock Alert: Halper Sadeh LLC is Investigating Whether Supernus Pharmaceuticals, Inc. is Obtaining a Fair Price for its Shareholders

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating the sale of Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) to Indivior Pharmaceuticals, Inc. for 1.5401 common shares of Indivior for each share of Supernus.Halper Sadeh encourages Supernus shareholders to click here to learn more about their rights and options or contact Daniel Sadeh or Zachary Halper free of charge at (212) 763-0060 or [email protected] or [email protected] investigation con.

Supernus Pharmaceuticals, Inc. (SUPN)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Supernus Pharmaceuticals, Inc. (SUPN)

SUPN vs. TEVA: Which Stock Should Value Investors Buy Now?